Extracellular vesicles as a platform for 'liquid biopsy' in glioblastoma patients

Expert Review of Molecular Diagnostics

Volumn 14, Issue 7, 2014, Pages 819-825

  Santiago Dieppa, David R ^a,b   Steinberg, Jeffrey ^a,b   Gonda, David ^a,b   Cheung, Vincent J ^a,b   Carter, Bob S ^a,b   Chen, Clark C ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

biomarker; exosomes; extracellular vesicle; glioma; microvesicle

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; ISOCITRATE DEHYDROGENASE 1; MESSENGER RNA; MICRORNA; MICRORNA 21; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; MIRN21 MICRORNA, HUMAN;

BLOOD ANALYSIS; CELL ISOLATION; CELL MATURATION; CELL SURFACE; CELL VACUOLE; CEREBROSPINAL FLUID ANALYSIS; DENDRITIC CELL; EXOSOME; EXTRACELLULAR VESICLE; GLIOBLASTOMA; HUMAN; NONHUMAN; PROTEOMICS; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR BIOPSY; BRAIN NEOPLASMS; GENETICS; PATHOLOGY; TUMOR MICROENVIRONMENT;

BRAIN NEOPLASMS; EXOSOMES; GLIOBLASTOMA; HUMANS; ISOCITRATE DEHYDROGENASE; MICRORNAS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MICROENVIRONMENT;

EID: 84906306079     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2014.943193     Document Type: Review

References (61)

1. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. see comment Lancet Oncol 2009; 10(5):459-66
2. Stupp R, Mason WP, Van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987-96
3. Preusser M, De Ribaupierre S, Wohrer A, et al. Current concepts and management of glioblastoma. Ann Neurol 2011;70(1):9-21
4. Sorensen AG, Batchelor TT, Wen PY, et al. Response criteria for glioma. Nat Clin Pract Oncol 2008;5(11):634-44
5. Rahmathulla G, Marko NF, Weil RJ. Cerebral radiation necrosis: A review of the pathobiology, diagnosis and management considerations. J Clin Neurosci 2013;20(4): 485-502
6. Law M. Advanced imaging techniques in brain tumors. Cancer Imaging 2009;9:Spec No A S4-9
7. Lemort M, Canizares-Perez AC, Van Der Stappen A, Kampouridis S. Progress in magnetic resonance imaging of brain tumours. Curr Opin Oncol 2007; 19(6):616-22
8. Waters JD, Gonda DD, Reddy H, et al. Diagnostic yield of stereotactic needle-biopsies of sub-cubic centimeter intracranial lesions. Surg Neurol Int 2013; 4(Suppl 3):S176-81
9. Geiger H, Schleimer D, Nattamai KJ, et al. Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood 2006; 107(7):3010-11
10. Chen CC, Taniguchi T, D'Andrea A. The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents. J Mol Med (Berl) 2007;85(5):497-509
11. Mojas N, Lopes M, Jiricny J. Mismatch repair-dependent processing of methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA. Genes Dev 2007;21(24):3342-55
12. Bodell WJ, Gaikwad NW, Miller D, Berger MS. Formation of DNA adducts and induction of lacI mutations in Big Blue Rat-2 cells treated with temozolomide: Implications for the treatment of low-grade adult and pediatric brain tumors. Cancer Epidemiol Biomarkers Prev 2003;12(6): 545-51
13. Tian T, Olson S, Whitacre JM, Harding A. The origins of cancer robustness and evolvability. Integr Biol (Camb) 2011;3(1): 17-30
14. Silva AS, Gatenby RA, Gillies RJ, Yunes JA. A quantitative theoretical model for the development of malignancy in ductal carcinoma in situ. J Theor Biol 2010; 262(4):601-13
15. Akers JC, Ramakrishnan V, Kim R, et al. MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): A platform for glioblastoma biomarker development. PLoS One 2013;8(10):e78115
16. Chen WW, Balaj L, Liau LM, et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic Acids 2013;2: E109
17. Shao H, Chung J, Balaj L, et al. Protein typing of circulating microvesicles allows real-Time monitoring of glioblastoma therapy. Nat Med 2012;18(12):1835-40
18. Skog J, Wurdinger T, Van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008;10(12):1470-6
19. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: Monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013;10(8):472-84
20. Akers J, Gonda D, Kim R, et al. Biogenesis of extracellular vesicles (EV): Exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol 2013; 113(1):1-11
21. Bianchi E, Doe B, Goulding D, Wright GJ. Juno is the egg Izumo receptor and is essential for mammalian fertilization. Nature 2014;508(7497):483-7
22. Gonda DD, Akers JC, Kim R, et al. Neuro-oncologic applications of exosomes, microvesicles, and other nano-sized extracellular particles. Neurosurgery 2013; 72(4):501-10
23. Johnstone RM, Adam M, Hammond JR, et al. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J Biol Chem 1987;262(19): 9412-20
24. Ohshima K, Inoue K, Fujiwara A, et al. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS ONE 2010;5(10):e13247
25. Frohlich D, Fruhbeis C, Amphornrat J, et al Crosstalk between neurons and glia involving exosomes as vesicular carriers of RNA and proteins [abstract In: 2012 International Society for Extracellular Vesicles meeting; Gothenburg, Sweden; 2012
26. Zhang Y, Liu D, Chen X, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 2010; 39(1):133-44
27. Zomer A, Vendrig T, Hopmans ES, et al. Exosomes: Fit to deliver small RNA. Commun Integr Biol 2010;3(5):447-50
28. Angelucci A, D'Ascenzo S, Festuccia C, et al. Vesicle-Associated urokinase plasminogen activator promotes invasion in prostate cancer cell lines. Clin Exp Metastasis 2000;18(2):163-70
29. Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, et al. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother 2006;55(7):808-18
30. Ginestra A, La Placa MD, Saladino F, et al. The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res 1998;18(5A):3433-7
31. Hakulinen J, Sankkila L, Sugiyama N, et al. Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. J Cell Biochem 2008;105(5): 1211-18
32. Castellana D, Zobairi F, Martinez MC, et al. Membrane microvesicles as actors in the establishment of a favorable prostatic tumoral niche: A role for activated fibroblasts and CX3CL1-CX3CR1 axis. Cancer Res 2009;69(3):785-93
33. Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res 2011;71(11):3792-801
34. Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012;18(6):883-91
35. Admyre C, Johansson SM, Paulie S, Gabrielsson S. Direct exosome stimulation of peripheral human T cells detected by ELISPOT. Eur J Immunol 2006;36(7): 1772-81
36. Obregon C, Rothen-Rutishauser B, Gitahi SK, et al. Exovesicles from human activated dendritic cells fuse with resting dendritic cells, allowing them to present alloantigens. Am J Pathol 2006;169(6): 2127-36
37. Szajnik M, Czystowska M, Szczepanski MJ, et al. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLoS One 2010;5(7):e11469
38. Pincetic A, Leis J. The mechanism of budding of retroviruses from cell membranes. Adv Virol 2009;2009: 6239691-9
39. Raposo G, Nijman HW, Stoorvogel W, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med 1996;183(3):1161-72
40. Raposo GA, Stoorvogel W. Extracellular vesicles: Exosomes, microvesicles, and friends. J Cell Biol 2013;200(4):373-83
41. Lamparski HG, Metha-Damani A, Yao JY, et al. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 2002; 270(2):211-26
42. Clayton A, Court J, Navabi H, et al. Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J Immunol Methods 2001;247(1-2):163-74
43. Koga K, Matsumoto K, Akiyoshi T, et al. Purification, characterization and biological significance of tumor-derived exosomes. Anticancer Res 2005;25(6A):3703-7
44. Rekker K, Saare M, Roost AM, et al. Comparison of serum exosome isolation methods for microRNA profiling. Clin Biochem 2014;47(1-2):135-8
45. Tauro BJ, Greening DW, Mathias RA, et al. Comparison of ultracentrifugation, density gradient separation, and immunoaffinity capture methods for isolating human colon cancer cell line LIM1863-derived exosomes. Methods 2012; 56(2):293-304
46. Rieseberg M, Kasper C, Reardon KF, Scheper T. Flow cytometry in biotechnology. Appl Microbiol Biotechnol 2001;56(3-4):350-60
47. Witwer KW, Buzas EI, Bemis LT, et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J Extracell Vesicles 2013;2
48. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol 2006;Chapter 3, Unit 3 22
49. Soo CY, Song Y, Zheng Y, et al. Nanoparticle tracking analysis monitors microvesicle and exosome secretion from immune cells. Immunology 2012;136(2): 192-7
50. Van Der Pol E, Coumans F, Varga Z, et al. Innovation in detection of microparticles and exosomes. J Thromb Haemost 2013; 11(Suppl 1):36-45
51. Roberts GS, Kozak D, Anderson W, et al. Tunable nano/micropores for particle detection and discrimination: Scanning ion occlusion spectroscopy. Small 2010;6(23): 2653-8
52. Aldape KD, Ballman K, Furth A, et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004;63(7):700-7
53. Sugawa N, Ekstrand AJ, James CD, Collins VP. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA 1990;87(21):8602-6
54. Gan HK, Kaye AH, Luwor RB. The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci 2009;16(6): 748-54
55. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360(8):765-73
56. Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: Mechanisms, models, and clinical opportunities. Cancer Discov 2013;3(7):730-41
57. Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;483(7390):479-83
58. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005; 65(14):6029-33
59. Krichevsky AM, Gabriely G. miR-21: A small multi-faceted RNA. J Cell Mol Med 2009;13(1):39-53
60. Balic M, Williams A, Lin H, et al. Circulating tumor cells: From bench to bedside. Annu Rev Med 2013;64:31-44
61. De Mattos-Arruda L, Cortes J, Santarpia L, et al. Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol 2013;10(7):377-89